Literature DB >> 34088723

An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.

Balazs Acs1,2,3, David L Rimm1,4, Yalai Bai5, Kimberly Cole5, Sandra Martinez-Morilla5, Fahad Shabbir Ahmed5, Jon Zugazagoitia5, Johan Staaf6, Ana Bosch6,7, Anna Ehinger8, Emma Nimeus6,9, Johan Hartman2,3.   

Abstract

PURPOSE: Although tumor-infiltrating lymphocytes (TIL) assessment has been acknowledged to have both prognostic and predictive importance in triple-negative breast cancer (TNBC), it is subject to inter and intraobserver variability that has prevented widespread adoption. Here we constructed a machine-learning based breast cancer TIL scoring approach and validated its prognostic potential in multiple TNBC cohorts. EXPERIMENTAL
DESIGN: Using the QuPath open-source software, we built a neural-network classifier for tumor cells, lymphocytes, fibroblasts, and "other" cells on hematoxylin-eosin (H&E)-stained sections. We analyzed the classifier-derived TIL measurements with five unique constructed TIL variables. A retrospective collection of 171 TNBC cases was used as the discovery set to identify the optimal association of machine-read TIL variables with patient outcome. For validation, we evaluated a retrospective collection of 749 TNBC patients comprised of four independent validation subsets.
RESULTS: We found that all five machine TIL variables had significant prognostic association with outcomes (P ≤ 0.01 for all comparisons) but showed cell-specific variation in validation sets. Cox regression analysis demonstrated that all five TIL variables were independently associated with improved overall survival after adjusting for clinicopathologic factors including stage, age, and histologic grade (P ≤ 0.0003 for all analyses).
CONCLUSIONS: Neural net-driven cell classifier-defined TIL variables were robust and independent prognostic factors in several independent validation cohorts of TNBC patients. These objective, open-source TIL variables are freely available to download and can now be considered for testing in a prospective setting to assess clinical utility.See related commentary by Symmans, p. 5446. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34088723      PMCID: PMC8530841          DOI: 10.1158/1078-0432.CCR-21-0325

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

2.  Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Authors:  Carsten Denkert; Stephan Wienert; Audrey Poterie; Sibylle Loibl; Jan Budczies; Sunil Badve; Zsuzsanna Bago-Horvath; Anita Bane; Shahinaz Bedri; Jane Brock; Ewa Chmielik; Matthias Christgen; Cecile Colpaert; Sandra Demaria; Gert Van den Eynden; Giuseppe Floris; Stephen B Fox; Dongxia Gao; Barbara Ingold Heppner; S Rim Kim; Zuzana Kos; Hans H Kreipe; Sunil R Lakhani; Frederique Penault-Llorca; Giancarlo Pruneri; Nina Radosevic-Robin; David L Rimm; Stuart J Schnitt; Bruno V Sinn; Peter Sinn; Nicolas Sirtaine; Sandra A O'Toole; Giuseppe Viale; Koen Van de Vijver; Roland de Wind; Gunter von Minckwitz; Frederick Klauschen; Michael Untch; Peter A Fasching; Toralf Reimer; Karen Willard-Gallo; Stefan Michiels; Sherene Loi; Roberto Salgado
Journal:  Mod Pathol       Date:  2016-07-01       Impact factor: 7.842

3.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Authors:  S Loi; S Michiels; R Salgado; N Sirtaine; V Jose; D Fumagalli; P-L Kellokumpu-Lehtinen; P Bono; V Kataja; C Desmedt; M J Piccart; S Loibl; C Denkert; M J Smyth; H Joensuu; C Sotiriou
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

4.  Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer.

Authors:  Han Le; Rajarsi Gupta; Le Hou; Shahira Abousamra; Danielle Fassler; Luke Torre-Healy; Richard A Moffitt; Tahsin Kurc; Dimitris Samaras; Rebecca Batiste; Tianhao Zhao; Arvind Rao; Alison L Van Dyke; Ashish Sharma; Erich Bremer; Jonas S Almeida; Joel Saltz
Journal:  Am J Pathol       Date:  2020-04-08       Impact factor: 4.307

5.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

6.  The Cancer Genome Atlas Pan-Cancer analysis project.

Authors:  John N Weinstein; Eric A Collisson; Gordon B Mills; Kenna R Mills Shaw; Brad A Ozenberger; Kyle Ellrott; Ilya Shmulevich; Chris Sander; Joshua M Stuart
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330

7.  Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.

Authors:  J H Park; S F Jonas; G Bataillon; C Criscitiello; R Salgado; S Loi; G Viale; H J Lee; M V Dieci; S-B Kim; A Vincent-Salomon; G Curigliano; F André; S Michiels
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

8.  Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

Authors:  Yinyin Yuan; Henrik Failmezger; Oscar M Rueda; H Raza Ali; Stefan Gräf; Suet-Feung Chin; Roland F Schwarz; Christina Curtis; Mark J Dunning; Helen Bardwell; Nicola Johnson; Sarah Doyle; Gulisa Turashvili; Elena Provenzano; Sam Aparicio; Carlos Caldas; Florian Markowetz
Journal:  Sci Transl Med       Date:  2012-10-24       Impact factor: 17.956

9.  Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.

Authors:  Johan Staaf; Dominik Glodzik; Åke Borg; Serena Nik-Zainal; Ana Bosch; Johan Vallon-Christersson; Christel Reuterswärd; Jari Häkkinen; Andrea Degasperi; Tauanne Dias Amarante; Lao H Saal; Cecilia Hegardt; Hilary Stobart; Anna Ehinger; Christer Larsson; Lisa Rydén; Niklas Loman; Martin Malmberg; Anders Kvist; Hans Ehrencrona; Helen R Davies
Journal:  Nat Med       Date:  2019-09-30       Impact factor: 53.440

10.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Authors:  Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

View more
  4 in total

1.  Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome.

Authors:  Giovanni Bocchialini; Ana-Iris Schiefer; Leonhard Müllauer; Jürgen Thanner; Jonas Bauer; Felizia Thaler; Maria Laggner; Cecilia Veraar; Walter Klepetko; Konrad Hötzenecker; José Ramon Matilla; Hendrik Jan Ankersmit; Bernhard Moser
Journal:  Br J Cancer       Date:  2022-06-24       Impact factor: 9.075

2.  CXCL13 expression in mouse 4T1 breast cancer microenvironment elicits antitumor immune response by regulating immune cell infiltration.

Authors:  Qizhi Ma; Yue Chen; Qing Qin; Fuchun Guo; Yong-Sheng Wang; Dan Li
Journal:  Precis Clin Med       Date:  2021-08-04

Review 3.  Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.

Authors:  Evangelos Tzoras; Ioannis Zerdes; Nikos Tsiknakis; Georgios C Manikis; Artur Mezheyeuski; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 4.  Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer.

Authors:  Davide Massa; Anna Tosi; Antonio Rosato; Valentina Guarneri; Maria Vittoria Dieci
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.